158 related articles for article (PubMed ID: 24771299)
1. A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Weaver A; Love SB; Larsen M; Shanyinde M; Waters R; Grainger L; Shearwood V; Brooks C; Gibson O; Young AM; Tarassenko L
Support Care Cancer; 2014 Oct; 22(10):2677-85. PubMed ID: 24771299
[TBL] [Abstract][Full Text] [Related]
2. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
[TBL] [Abstract][Full Text] [Related]
5. Oral capecitabine (Xeloda) in cancer treatment.
Doyle DP; Engelking C
Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
[No Abstract] [Full Text] [Related]
6. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Hennessy BT; Gauthier AM; Michaud LB; Hortobagyi G; Valero V
Ann Oncol; 2005 Aug; 16(8):1289-96. PubMed ID: 15890665
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
8. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
Craven O; Hughes CA; Burton A; Saunders MP; Molassiotis A
Eur J Cancer Care (Engl); 2013 May; 22(3):413-9. PubMed ID: 23527965
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
Daher Abdi Z; Lavau-Denes S; Prémaud A; Urien S; Sauvage FL; Martin J; Leobon S; Marquet P; Tubiana-Mathieu N; Rousseau A
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1285-93. PubMed ID: 24801171
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
[TBL] [Abstract][Full Text] [Related]
11. Mobile health for drug dose optimisation.
Larsen ME; Farmer A; Weaver A; Young A; Tarassenko L
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():1540-3. PubMed ID: 22254614
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
Wang X; Jin J; Li YX; Ren H; Fang H; Wang SL; Liu YP; Wang WH; Yu ZH; Song YW; Liu XF
World J Gastroenterol; 2014 Jan; 20(4):1067-73. PubMed ID: 24574780
[TBL] [Abstract][Full Text] [Related]
13. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
Figueiredo Junior AG; Forones NM
Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
Molassiotis A; Brearley S; Saunders M; Craven O; Wardley A; Farrell C; Swindell R; Todd C; Luker K
J Clin Oncol; 2009 Dec; 27(36):6191-8. PubMed ID: 19917849
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Ngan SY; Michael M; Mackay J; McKendrick J; Leong T; Lim Joon D; Zalcberg JR
Br J Cancer; 2004 Sep; 91(6):1019-24. PubMed ID: 15305186
[TBL] [Abstract][Full Text] [Related]
16. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
[TBL] [Abstract][Full Text] [Related]
17. Application of mobile phone technology for managing chemotherapy-associated side-effects.
Weaver A; Young AM; Rowntree J; Townsend N; Pearson S; Smith J; Gibson O; Cobern W; Larsen M; Tarassenko L
Ann Oncol; 2007 Nov; 18(11):1887-92. PubMed ID: 17921245
[TBL] [Abstract][Full Text] [Related]
18. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Rudek MA; Connolly RM; Hoskins JM; Garrett-Mayer E; Jeter SC; Armstrong DK; Fetting JH; Stearns V; Wright LA; Zhao M; Watkins SP; McLeod HL; Davidson NE; Wolff AC
Breast Cancer Res Treat; 2013 May; 139(1):135-43. PubMed ID: 23588952
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
[TBL] [Abstract][Full Text] [Related]
20. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
